EF
NKTR icon

Empowered Funds’s Nektar Therapeutics NKTR Stock Holding History

Empowered Funds’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Buy
+23,441
New +$1.72M 0.01% 1286
2018
Q4 		– Sell
-1,682
Closed -$1.54M – 105
2018
Q3 		$1.54M Buy
1,682
+341
+25% +$291K 0.46% 83
2018
Q2 		$969K Buy
1,341
+392
+41% +$452K 0.31% 92
2018
Q1 		$1.5M Buy
+949
New +$1.22M 0.55% 45

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Empowered Funds's NKTR Position: Q2 2026 in Review

Empowered Funds opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 23,441 shares worth $1.64M. The stake represents 0.01% of the portfolio and ranks #1286 among its holdings. This is a return to the name: Empowered Funds previously reported a position in NKTR as recently as Q3 2018.

Empowered Funds first reported a position in NKTR in Q1 2018 and has held it in 4 quarters since. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Empowered Funds held 23,441 shares of Nektar Therapeutics worth $1.64M as of Q2 2026.
  • Nektar Therapeutics was a new Empowered Funds position in Q2 2026.
  • Nektar Therapeutics made up 0.01% of Empowered Funds's portfolio in Q2 2026, its #1286 holding.
  • Empowered Funds first reported a position in Nektar Therapeutics in Q1 2018 and has held it in 4 quarters since.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.